Related Experiment Video
Updated: Apr 22, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.6K
Renal denervation therapy for resistant hypertension.
Mark Davis1, Ernesto L Schiffrin, Dominique Joyal
1Department of Medicine, Division of Cardiology, Jewish General Hospital, McGill University, 3755 Cote Ste-Catherine Rd, Suite E-215, Montreal, Quebec, H3T 1E2, Canada.
Current Treatment Options in Cardiovascular Medicine
|October 11, 2014
Summary
Renal sympathetic denervation, a procedure for resistant hypertension, showed promising results in early studies but failed efficacy endpoints in a recent trial. Further rigorous trials are needed to determine its role in managing high blood pressure.
Area of Science:
- Cardiology
- Interventional Cardiology
- Nephrology
Background:
- Resistant hypertension affects many patients, leading to significant cardiovascular risks.
- Limited pharmacologic options exist for patients with uncontrolled blood pressure.
- Renal sympathetic denervation emerged as a novel interventional treatment option.
Purpose of the Study:
- To evaluate the efficacy and safety of renal sympathetic denervation for resistant hypertension.
- To discuss the conflicting results between observational studies and recent sham-controlled trials.
- To reflect on the importance of rigorous clinical trials for novel medical technologies.
Main Methods:
- Percutaneous ablation of renal artery sympathetic nerves.
- Initial studies were primarily observational and unblinded.
- A recent rigorous single-blinded sham-controlled clinical trial was conducted.
Main Results:
- Observational studies reported significant systolic blood pressure reductions (25-30 mm Hg).
- A recent sham-controlled trial did not meet its primary efficacy endpoints.
- Conflicting results necessitate further investigation into the procedure's effectiveness.
Conclusions:
- Renal sympathetic denervation's role in treating resistant hypertension is currently investigational.
- The discrepancy in results highlights the need for robust clinical evidence before widespread adoption.
- Ongoing trials with different technologies aim to clarify the definitive role of renal denervation.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:22Heart Failure Drugs: Diuretics
1.3K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.3K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:30Heart Failure V: Medical Management
606
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
606